Please login to the form below

Not currently logged in
Email:
Password:

etanercept

This page shows the latest etanercept news and features for those working in and with pharma, biotech and healthcare.

Amgen raises forecasts after closing $13.4bn Otezla deal

Amgen raises forecasts after closing $13.4bn Otezla deal

Otezla slots into Amgen’s existing psoriasis and anti-inflammatory product range, which includes Enbrel (etanercept) and Amgevita, its biosimilar of AbbVie’s Humira (adalimumab) which is approved and already available

Latest news

More from news
Approximately 7 fully matching, plus 92 partially matching documents found.

Latest Intelligence

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    The UK has been especially proactive with biosimilars. Three biologics there – infliximab, rituximab and etanercept –underwent an average price reduction of 40% when their biosimilars were introduced.

  • The tipping point The tipping point

    Driving disparity. If we look across Europe at biosimilar penetration, even the recently launched infliximab and etanercept biosimilars show highly variable uptake between markets.

  • Deal Watch October 2016 Deal Watch October 2016

    For example Samsung Bioepis also based in South Korea, signed a deal with Merck &Co in 2013 for a range of biosimilars including infliximab, trastuzumab and etanercept (Amgen's Enbrel with ... The FDA accepted the Biologics Licence Application for

  • Cost containment and the German market Cost containment and the German market

    The main sales drivers are biopharmaceutical medicines like the monoclonal antibody adalimumab, TNF-alpha inhibitor etanercept as well as the oncologic drugs imatinib and enzalutamide.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    drugs Humira (adalimumab) and Enbrel (etanercept) - last year's first and third best selling drugs respectively - are also in the biosimilar firing line.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon. .

  • Infographic: RA Perceptions

    expect current market leaders Enbrel (etanercept) and Humira (adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’

  • Brand leaders in RA will lose market share, predict rheumatologists

    leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics